Drug data last refreshed 2d ago
RETIN-A (tretinoin) is a topical retinoid cream approved in 1988 for acne vulgaris treatment. It works by decreasing follicular epithelial cell cohesiveness and stimulating cell turnover to extrude comedones, with minimal systemic absorption (<0.3% bioavailable). The exact mechanism remains incompletely understood but involves modulation of cell differentiation and proliferation.
Product is in late-stage lifecycle with modest Part D utilization; brand team likely focused on retention and competitive positioning against newer formulations.
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
Worked on RETIN-A at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moRETIN-A generates minimal linked job openings, reflecting its mature lifecycle status and modest commercial footprint ($1M Part D spend). Career opportunities are concentrated in defensive brand management, generic competition response, and portfolio strategy within dermatology.